» Articles » PMID: 35342478

Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas

Overview
Specialty Endocrinology
Date 2022 Mar 28
PMID 35342478
Authors
Affiliations
Soon will be listed here.
Abstract

Non-functioning pituitary tumors (NFPA) are usually large at the time of diagnosis and present with symptoms caused by compression on the neighbouring structures. Transsphenoidal resection of the tumor is the first-line treatment but in many cases complete tumor resection cannot be attained. Close follow-up with repeated hormonal assessment and pituitary imaging is recommended after surgery. During follow-up of the tumor remnant sometimes radiotherapy is used to stop or prevent tumor progression. Medical treatment with dopamine agonists (DA) is the mainstay in the management of prolactinomas. For NFPA several small series or case reports suggested beneficial effects with tumor shrinkage in some cases. The aim of the current paper is to summarize the available evidence related to the potential efficacy of DA medical treatment in NFPA while underlining that in the absence of randomized, placebo-controlled studies, no final conclusion on the efficacy of these drugs in the treatment of NFPA can be drawn.

Citing Articles

Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.

Iglesias P, Biagetti B, Araujo-Castro M, Alcazar V, Guerrero-Perez F, Rivero N J Neurooncol. 2022; 160(2):351-359.

PMID: 36355257 DOI: 10.1007/s11060-022-04149-7.

References
1.
Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T . Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol. 2016; 175(1):63-72. DOI: 10.1530/EJE-16-0206. View

2.
Nobels F, de Herder W, van den Brink W, Kwekkeboom D, Hofland L, Zuyderwijk J . Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. Eur J Endocrinol. 2000; 143(5):615-21. DOI: 10.1530/eje.0.1430615. View

3.
Johnston D, Hall K, McGregor A, Ross W, Kendall-Taylor P, Hall R . Bromocriptine therapy for "nonfunctioning" pituitary tumors. Am J Med. 1981; 71(6):1059-61. DOI: 10.1016/0002-9343(81)90342-9. View

4.
Kwekkeboom D, Hofland L, Van Koetsveld P, Singh R, van den Berge J, Lamberts S . Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture. J Clin Endocrinol Metab. 1990; 71(3):718-24. DOI: 10.1210/jcem-71-3-718. View

5.
Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L . Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine. 2001; 14(3):329-36. DOI: 10.1385/endo:14:3:329. View